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With the BLyS inhibitor Belimumab recently approved by
the United States Food and Drug administration as the ﬁrst
treatmentforSystemicLupusErythematosusindecades,and
the ongoing trials of other cytokine inhibitors as potential
therapeutic agents for lupus, the potential of cytokines in the
realmoftherapeutictargetsforlupusisbeginningtoreachits
promise.Thesefascinatingmoleculesregulatemultiplefacets
of the immune system and, as such, have been extensively
examined for a role in many diﬀerent aspects of lupus etiolo-
gy, pathogenesis, and regulation.
This special issue contains novel research about three
cytokines and their roles in lupus. Alleles of Osteopontin
were found to be associated with multiple clinical manifesta-
tions of lupus (T. Trivedi et al.). The feasibility of Neutrophil
gelatinase-associated lipocalin as a biomarker for kidney
damage was assessed (Y.-L. Yang et al.). The lupus risk hap-
lotype of the Interferon regulatory factor ﬁve gene was found
to inﬂuence gene expression in three key pathways that have
the potential to inﬂuence the development or pathogenesis
of lupus (J. M. Guthridge et al.).
The reviews included in this issue summarize the most
current research on the multiple roles of cytokines in lupus
(K. Ohl and K. Tenbrock). The inﬂuences of cytokines on
T cell subsets in lupus and how those subsets relate to
lupus are discussed (A. Okamoto et al., K. Miyake et al.).
The roles of cytokines in clinical manifestations, such as
nephritis (Y. Iwata et al.), neuropsychiatric manifestations,
cutaneous lupus, and premature atherosclerosis (T. P.
Karageorgas et al.), are a major focus of this issue.
Cytokine research holds tremendous promise for under-
standing and treating lupus. We thank all those who con-
tributed articles for this special issue and those who reviewed
and in other ways contributed. We hope that this avenue of
research will continue to be supported and be a beneﬁt to the
livesofthosesuﬀeringwiththiscomplexanddiﬃcultdisease.
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